H.C. Wainwright lowered the firm’s price target on Oric Pharmaceuticals to $15 from $16 and keeps a Buy rating on the shares after the company presented initial clinical results for its orally-administered CD73 inhibitor, ORIC-533, in heavily pretreated multiple myeloma patients. The firm pushed back ORIC-533’s potential U.S. market launch to 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORIC:
- Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
- Oric: Phase 1 dose escalation data for ORIC-533 shows strong safety profile
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- Oric Pharmaceuticals reports Q3 EPS (44c), consensus (46c)
- ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
